X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Venetoclax,Ibrutinib
Therapeutic Area: Oncology Product Name: Venclexta
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
Details:
Ibrutinib plus venetoclax is an investigational fixed-duration combination. Patients received 3 cycles of ibrutinib lead-in followed by 12 cycles of ibrutinib + venetoclax (Ibr 420 mg/day PO; Ven ramp up to 400 mg/day PO).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ibrutinib,Venetoclax
Therapeutic Area: Oncology Product Name: Imbruvica
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Janssen Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2020
Details:
The results show the ibrutinib plus venetoclax combination providing continued disease-free survival for CLL patients once treatment is complete.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Venetoclax,Ibrutinib
Therapeutic Area: Oncology Product Name: Venclexta
Highest Development Status:
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
